1 month Top Biotech Neurogene Crashes 44%, Wiping Out Its Sprint On A $200 Million Deal Investor's Business Daily
Biotech stock Neurogene collapsed Tuesday after a patient experienced a serious side effect in the company’s Rett syndrome study.
The post Top Biotech Neurogene Crashes 44%, Wiping Out Its Sprint On A $200 Million Deal appeared first on Investor's…